Article
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Bulletin du cancer - 1 Apr 2018
Loriot Marie-Anne, Ciccolini Joseph, Thomas Fabienne, Barin-Le-Guellec Chantal, Royer Bernard, Milano Gérard, Picard Nicolas, Becquemont Laurent, Verstuyft Céline, Narjoz Céline, Schmitt Antonin, Bobin-Dubigeon Christine, Harle Alexandre, Paci Angelo, Poinsignon Vianney, Quaranta Sylvie, Evrard Alexandre, Hennart Benjamin, Broly Franck, Fonrose Xavier, Lafay-Chebassier Claire, Wozny Anne-Sophie, Masskouri Fadil, Boyer Jean-Christophe, Etienne-Grimaldi Marie-Christine
Abstract excerpt
Fluoropyrimidines (FU) are still the most prescribed anticancer drugs for the treatment of solid cancers. However, fluoropyrimidines cause severe toxicities in 10 to 40% of patients and toxic deaths in 0.2 to 0.8% of patients, resulting in a real public health problem. The main origin of FU-related toxicities is a deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme of 5-FU catabolism....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.